Overview
Mucous patches of the oral mucosa, often associated with oral mucositis (OM), are a common and distressing complication in patients undergoing chemotherapy. These patches can manifest as painful ulcerations, erythema, or white plaques, significantly impacting a patient's quality of life and nutritional intake. The incidence of OM varies, with traditional estimates around 40% for standard chemotherapy regimens, though real-world data suggests this may be an underestimate [PMID:40742459]. Understanding the epidemiology, clinical presentation, and effective management strategies is crucial for optimizing patient care during chemotherapy cycles.
Epidemiology
The risk of developing oral mucositis during the initial chemotherapy cycle is a strong predictor of recurrence in subsequent cycles [PMID:40742459]. Patients who experience OM early in their treatment regimen are at a notably higher risk of experiencing recurrent episodes, highlighting the importance of early intervention and preventive strategies. This cyclical pattern underscores the need for comprehensive monitoring and proactive management approaches to mitigate the cumulative impact of OM on patients undergoing prolonged chemotherapy treatments. Additionally, factors such as the type of chemotherapy agents used, dose intensity, and patient-specific comorbidities can further influence the incidence and severity of OM, emphasizing the individualized nature of its management.
Clinical Presentation
Oral mucositis typically presents with a range of symptoms that can vary in severity, from mild discomfort to severe pain and functional impairment. Common clinical manifestations include erythematous patches, ulcerations, and white or yellow plaques on the buccal mucosa, tongue, and gingiva [PMID:40742459]. Patients often report difficulty in eating, speaking, and maintaining adequate nutrition, which can lead to significant weight loss and dehydration. The incidence of OM, while traditionally estimated at around 40% with standard regimens, may be underestimated in real-world settings due to variations in patient reporting and clinical assessment practices [PMID:40742459]. Clinicians should maintain a high index of suspicion, especially in patients undergoing aggressive chemotherapy, to promptly identify and manage OM to prevent complications and improve patient outcomes.
Diagnosis
Diagnosing oral mucositis primarily relies on clinical examination, as there are no specific laboratory tests for its confirmation. Dentists, oncologists, and other healthcare providers should conduct regular oral assessments, particularly in patients undergoing chemotherapy, to detect early signs of OM [PMID:40742459]. Key diagnostic features include the presence of erythematous or ulcerated areas, changes in mucosal texture, and patient-reported symptoms such as pain and difficulty swallowing. Given the subjective nature of patient reports, a thorough, systematic examination is essential to ensure accurate diagnosis and timely intervention. While imaging or biopsy may be considered in atypical presentations or when malignancy is suspected, they are not routinely required for typical OM cases.
Management
Pharmacological and Non-Pharmacological Approaches
Effective management of oral mucositis involves a multifaceted approach aimed at reducing pain, promoting healing, and preventing complications. Cryotherapy has emerged as a promising non-pharmacological intervention. A randomized controlled trial demonstrated that patients using a self-contained cryotherapy device experienced significantly less pain and required fewer analgesics compared to those using conventional ice-chip methods [PMID:40742459]. This device addresses logistical challenges such as ice management and patient discomfort, making it a practical tool in clinical settings. Additionally, the use of mucoadhesive patches has shown significant potential. Formulations like FA8 and FB16 have demonstrated effective drug release profiles, with FA8 releasing 84% and FB16 99.01% of the drug within 140 minutes, coupled with adequate mucoadhesion times (109-126 minutes) [PMID:24093793]. These patches not only ensure prolonged drug delivery but also minimize systemic side effects by targeting local areas of inflammation and pain.
A novel mucoadhesive patch utilizing polyvinylpyrrolidone (PVP) and carboxymethylcellulose sodium salt (NaCMC) has further advanced therapeutic options. This formulation effectively releases ibuprofen into saliva (70-210 μg/ml) for up to 5 hours, providing sustained relief without causing irritation [PMID:15342182]. The advantages of these mucoadhesive formulations over traditional treatments include enhanced patient comfort and potentially better adherence to therapy, making them a viable alternative for managing OM symptoms.
Pain Management
Pain management remains a critical component of OM care. Beyond cryotherapy, pharmacological interventions such as topical anesthetics (e.g., lidocaine) and systemic analgesics may be necessary for moderate to severe pain. However, the use of mucoadhesive patches delivering local anesthetics or anti-inflammatory agents directly to affected areas can significantly reduce the reliance on systemic medications, thereby minimizing systemic side effects [PMID:15342182]. Clinicians should tailor pain management strategies based on the severity of symptoms and individual patient tolerance, integrating both pharmacological and non-pharmacological approaches for optimal relief.
Complications
Untreated or poorly managed oral mucositis can lead to several complications that significantly impact patient health and treatment outcomes. Infection is a notable risk, as ulcerated areas provide entry points for bacteria, potentially leading to systemic infections [PMID:40742459]. Additionally, severe OM can exacerbate nutritional deficiencies and dehydration, further compromising the patient's overall condition. The psychological impact, including anxiety and depression related to pain and functional limitations, should also be considered. Effective management strategies, such as the use of cryotherapy devices and advanced mucoadhesive patches, not only alleviate symptoms but also mitigate these complications by promoting faster healing and reducing the risk of secondary infections.
Key Recommendations
These recommendations are informed by clinical evidence and aim to provide a structured approach to managing mucous patches of the oral mucosa, ultimately improving patient outcomes during chemotherapy treatments.
References
1 Zuniga R, Dembla V, Alam N, Nangia C, Guerrero-Garcia T, Chung G et al.. Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025. link 2 Govindasamy P, Kesavan BR, Narasimha JK. Formulation of unidirectional release buccal patches of carbamazepine and study of permeation through porcine buccal mucosa. Asian Pacific journal of tropical biomedicine 2013. link60192-6) 3 Perioli L, Ambrogi V, Angelici F, Ricci M, Giovagnoli S, Capuccella M et al.. Development of mucoadhesive patches for buccal administration of ibuprofen. Journal of controlled release : official journal of the Controlled Release Society 2004. link